Supernus Pharmaceuticals | SUPN - Current Liabilities


Supernus Pharmaceuticals reported $373.93M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Abbott USD 18.38B 1.88B Mar/2026
ANI Pharmaceuticals USD 239.51M 38.6M Mar/2026
Aurora Cannabis CAD 145.94M 21.82M Dec/2025
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Canopy Growth CAD 98.29M 17.19M Dec/2025
Cara Therapeutics USD 11.04M 2K Dec/2025
Corcept Therapeutics USD 149.18M 16.9M Mar/2026
Eisai JPY 340.25B 47.42B Mar/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Novo Nordisk DKK 225.16B 9.5B Mar/2026
Pacira USD 108.79M 11.8M Mar/2026
Perrigo USD 997.6M 15.3M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Supernus Pharmaceuticals USD 373.93M 35.76M Mar/2026
United Therapeutics USD 599.1M 38.5M Mar/2026
Xeris Pharmaceuticals USD 118.59M 9.02M Mar/2026